Form 4: Precision BioSciences Director Kevin Buehler Acquires Shares in Open Market Transaction

Precision BioSciences director Kevin Buehler purchased 4,320 shares of common stock at a weighted average price of $4.88 on December 27, 2024.

Summary

• Kevin Buehler, a director at Precision BioSciences, acquired 4,320 shares of the company's common stock on December 27, 2024.
• The shares were purchased at a weighted average price of $4.88 per share.
• The transactions occurred in multiple trades with prices ranging from $4.73 to $4.94.
• Following the transaction, Buehler directly owns 8,712 shares of Precision BioSciences stock.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of insider trading activity. While the purchase could be seen as a positive sign, it's not a major event that would significantly impact sentiment.

Positives

• The director's purchase of shares could be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Insider trading disclosures are a standard practice for all publicly listed companies, ensuring transparency and compliance with securities regulations.
• The reporting of transactions by directors is a common occurrence and is comparable to similar filings by directors of other publicly traded companies.

Stakeholder Impact

• The purchase of shares by a director may be viewed positively by shareholders, potentially indicating confidence in the company's future.

Key Dates

Keywords

Precision BioSciences, insider trading, stock purchase, Kevin Buehler, director, DTIL, SEC Form 4